The Effect of Benralizumab On Allergen-Induced Responses In Subjects With Mild Allergic Asthma - 01/02/21
Doi : 10.1016/j.jaci.2020.12.563
Gail Gauvreau 1, Roma Sehmi, PhD 1, J. FitzGerald, MD 2, Richard Leigh, MD PhD 3, Donald Cockcroft, MD FAAAAI 4, Beth Davis, PhD 4, Irvin Mayers, MD 5, Louis-Philippe Boulet, MD FRCPC 6, Brittany Salter, MD, PhD 1, Ruth Cusack, MD 1, Imran Satia, MD, PhD 1, Kieran Killian, MD 1, Patrick Mitchell, MB BCh 3, Viktoria Werkstrom, MD, PhD 7, Tomasz Durzynski, MD, PhD 8, Kathryn Shoemaker, MS 9, Rohit Katial, MD FAAAAI 9, Maria Jison 9, Paul Newbold, PhD 9, Paul O'Byrne, MD 1
1 McMaster University
2 University of BC
3 University of Calgary
4 University of Saskatoon
5 University of Alberta
6 Laval University
7 AstraZeneca, Sweden
8 AstraZeneca, Poland
9 AstraZeneca, USA
500
Il testo completo di questo articolo è disponibile in PDF.Mappa
© 2020
Pubblicato da Elsevier Masson SAS.
Vol 147 - N° 2S
P. AB157 - Febbraio 2021 Ritorno al numero
Articolo precedente
- Tezepelumab Efficacy in Patients with Allergic and Non-Allergic Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study
- Jonathan Corren, Gene Colice, Kinga Salapa, Karin Bowen, Jean-Pierre Llanos-Ackert
- Biologic Pathways Involved In Chronic Spontaneous Urticaria And Response To Benralizumab Treatment
- Debayoti Ghosh, Umesh Singh, Jonathan Bernstein
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?